Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.32%
median of 697 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
MapLight Therapeutics, Inc.
Market Cap
$397.78M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
N/A
Market Cap
$402.82M
Gross Margin
68.83%
TTM Avg
69.91%
3Y Avg
69.67%
5Y Avg
69.68%
Market Cap
$388.79M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
25.00%
5Y Avg
40.00%
Market Cap
$409.27M
Gross Margin
77.34%
TTM Avg
76.74%
3Y Avg
77.57%
5Y Avg
77.57%
Market Cap
$385.22M
Gross Margin
69.59%
TTM Avg
67.69%
3Y Avg
68.42%
5Y Avg
70.65%
Market Cap
$412.14M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
12.37%
Market Cap
$416.01M
Gross Margin
0.00%
TTM Avg
-125.52%
3Y Avg
-62.76%
5Y Avg
-41.84%
Market Cap
$380.02M
Gross Margin
95.50%
TTM Avg
97.75%
3Y Avg
98.88%
5Y Avg
1.50%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MapLight Therapeutics, Inc. (MPLT) | $397.78M | 0.00% | 0.00% | 0.00% | N/A |
| Myriad Genetics, Inc. (MYGN)vs › | $402.82M | 68.83% | 69.91% | 69.67% | 69.68% |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $388.79M | 0.00% | 0.00% | 25.00% | 40.00% |
| Carlsmed, Inc. (CARL)vs › | $404.24M | 76.63% | 74.56% | 73.66% | 73.66% |
| Shoulder Innovations, Inc. (SI)vs › | $409.27M | 77.34% | 76.74% | 77.57% | 77.57% |
| Orthofix Medical Inc. (OFIX)vs › | $385.22M | 69.59% | 67.69% | 68.42% | 70.65% |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $412.14M | 0.00% | 0.00% | 0.00% | 12.37% |
| Neurogene Inc. (NGNE)vs › | $416.01M | 0.00% | -125.52% | -62.76% | -41.84% |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $380.02M | 95.50% | 97.75% | 98.88% | 1.50% |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $416.33M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-03-31 | 0.00% |
